FDA approves GSK's neladalkib for ALK-positive non-small cell lung cancer
The FDA granted accelerated approval to neladalkib (Nelkarmi), a kinase inhibitor from Nuvalent acquired by GSK, for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer who have previously been treated.